Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese adverse drug event report database: a retrospective pharmacovigilance study

Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese adverse drug event report database: a retrospective pharmacovigilance study

Abstract Background The Anticholinergic Risk Scale and Total Anticholinergic Load were developed to assess the risks associated with anticholinergic drugs. Recently, the Japan Anticholinergic Risk Scale was introduced; however, the total anticholinergic load for adverse events has not been clarified...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yusuke Kan, Maki Doi, Yoshihiro Uesawa
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	Journal of Pharmaceutical Health Care and Sciences
Subjects:	JADER Japan anticholinergic risk scale Total anticholinergic load Anticholinergic syndrome
Online Access:	https://doi.org/10.1186/s40780-025-00413-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Polypharmacy and anticholinergic burden scales in older adults: a cross-sectional study among psychiatric outpatients in a tertiary care hospital
by: Manjunath Bidarolli, et al.
Published: (2025-01-01)

Comparison Of Outcome And Side Effects Profile Of Treatment Of Overactive Bladder With Different Classes Of Drugs
by: Nazish Sarfraz, et al.
Published: (2023-12-01)

Anticholinergic burden and behavioral and psychological symptoms in older patients with cognitive impairment
by: Sabrina Pistorio, et al.
Published: (2025-02-01)

Sedative load and anticholinergic burden among older adults in Slovenia over a decade: Potential for optimization of pharmacotherapy
by: Jazbar Janja, et al.
Published: (2024-06-01)

The utility of Glaucoma Information Cards for grasping glaucoma subtypes: a single-center pilot study
by: Yukinori Yamada, et al.
Published: (2025-02-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Lisi Xu, et al.
Published: (2025-01-01)

Assessing the health implications of anticholinergic drugs in older people
by: Mariangela Boccardi, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile
by: Astri Budikayanti, et al.
Published: (2018-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
by: Yixuan Yang, et al.
Published: (2025-01-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
by: Shuai Zhao, et al.
Published: (2025-02-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of “Anticholinergic Spectrum Disorders”
by: Koji Hori, et al.
Published: (2016-01-01)

Automatic tool for the reconciliation of serious adverse events for pharmacovigilance: design and implementation of Reconciliaid
by: Sara Contu, et al.
Published: (2025-01-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

The Role of Dexmedetomidine in Pediatric Patients Presenting with an Anticholinergic Toxidrome
by: Mitchell Zekhtser, et al.
Published: (2021-01-01)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
by: Yang Hu, et al.
Published: (2020-01-01)

Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study
by: Alshareef H, et al.
Published: (2025-02-01)

Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database
by: Hunong Xiang, et al.
Published: (2025-01-01)

Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system
by: Ying Zhao, et al.
Published: (2024-11-01)

Adverse drug event detection using natural language processing: A scoping review of supervised learning methods.
by: Rachel M Murphy, et al.
Published: (2023-01-01)

A Comprehensive 10-Year Nationwide Pharmacovigilance Surveillance on Antibacterial Agents in Korea: Data Mining for Signal Detection of Trends and Seriousness of Adverse Events
by: Seon Hu Mo, et al.
Published: (2025-01-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Antisecretory Action of the Extract of the Aerial Parts of Eremomastax speciosa (Acanthaceae) Occurs through Antihistaminic and Anticholinergic Pathways
by: Amang André Perfusion, et al.
Published: (2014-01-01)

Impact of discontinuation of cephazolin prophylaxis on the incidence of postoperative adverse events in cataract surgery
by: Kazutaka Uchida, et al.
Published: (2025-01-01)

Exploration of the optimal deep learning model for english-Japanese machine translation of medical device adverse event terminology
by: Ayako Yagahara, et al.
Published: (2025-02-01)

Author Correction: Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system
by: Ying Zhao, et al.
Published: (2025-02-01)